NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $33.22 +1.72 (+5.46%) Closing price 04:00 PM EasternExtended Trading$32.62 -0.59 (-1.79%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AtriCure Stock (NASDAQ:ATRC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AtriCure alerts:Sign Up Key Stats Today's Range$31.41▼$33.4050-Day Range$29.24▼$34.9452-Week Range$20.20▼$43.11Volume1.34 million shsAverage Volume571,253 shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$50.67Consensus RatingBuy Company Overview AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Read More AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreATRC MarketRank™: AtriCure scored higher than 68% of companies evaluated by MarketBeat, and ranked 331st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtriCure has only been the subject of 3 research reports in the past 90 days.Read more about AtriCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.60) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -41.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -41.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.24% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently decreased by 0.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.24% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently decreased by 0.64%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News Sentiment0.98 News SentimentAtriCure has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.08 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for AtriCure this week, compared to 5 articles on an average week.Search Interest1 people have searched for ATRC on MarketBeat in the last 30 days. MarketBeat Follows2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,600.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRC Stock News HeadlinesAtriCure to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 28 at 8:00 AM | businesswire.comAtriCure (ATRC) Projected to Post Quarterly Earnings on TuesdayJuly 28 at 2:56 AM | americanbankingnews.comWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.July 28 at 2:00 AM | InvestorPlace (Ad)AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke PreventionJuly 15, 2025 | finance.yahoo.comAtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke PreventionJuly 15, 2025 | businesswire.comAtriCure, Inc. (ATRC) Latest Stock News & Headlines - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comAtriCure to Announce Second Quarter 2025 Financial ResultsJuly 8, 2025 | theglobeandmail.comInteresting ATRC Put And Call Options For August 15thJuly 2, 2025 | nasdaq.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $30.56 at the start of the year. Since then, ATRC shares have increased by 8.7% and is now trading at $33.22. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Tuesday, April, 29th. The medical device company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11. The business's revenue for the quarter was up 13.5% compared to the same quarter last year. Read the conference call transcript. Does AtriCure have any subsidiaries? AtriCure subsidiaries include these companies: SentreHEART. Who are AtriCure's major shareholders? Top institutional investors of AtriCure include Assenagon Asset Management S.A. (0.09%), Marks Group Wealth Management Inc (0.06%), Harbor Capital Advisors Inc. (0.05%) and Truist Financial Corp (0.04%). Insiders that own company stock include Salvatore Privitera, Vinayak Doraiswamy, Justin J Noznesky, Karl S Dahlquist, Karen Prange and Maggie Yuen. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings4/29/2025Today7/28/2025Next Earnings (Estimated)7/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,300Year Founded2000Price Target and Rating Average Price Target for AtriCure$50.67 High Price Target$60.00 Low Price Target$44.00 Potential Upside/Downside+57.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.70 million Net Margins-7.95% Pretax Margin-7.73% Return on Equity-5.68% Return on Assets-4.34% Debt Debt-to-Equity Ratio0.16 Current Ratio4.11 Quick Ratio2.88 Sales & Book Value Annual Sales$465.31 million Price / Sales3.42 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book3.40Miscellaneous Outstanding Shares49,510,000Free Float47,772,000Market Cap$1.59 billion OptionableOptionable Beta1.56 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ATRC) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.